Clinical Trials Logo

Lung Cancer, Nonsmall Cell clinical trials

View clinical trials related to Lung Cancer, Nonsmall Cell.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06231680 Recruiting - Clinical trials for Esophageal Carcinoma

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Start date: January 19, 2024
Phase: Phase 2
Study type: Interventional

To explore the dose and safety of thalidomide for the prevention and treatment of camrelizumab-induced reactive cutaneous capillary endothelial proliferation (RCCEP)

NCT ID: NCT06003075 Recruiting - Clinical trials for Lung Cancer, Nonsmall Cell

Induction Chemo-Nivo in Unresectable Stage III NSCLC

Start date: September 22, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the response rate, safety, and effectiveness of a combination therapy in patients with lung cancer.

NCT ID: NCT05860296 Recruiting - Clinical trials for Lung Cancer, Nonsmall Cell

Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

Start date: May 31, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

SLC-391 is a novel, potent and specific small molecule inhibitor of receptor tyrosine kinase AXL with desirable potency and pharmaceutical properties. The study is being done to evaluate the safety and pharmacokinetic (PK) profile of SLC-391 in combination with pembrolizumab in participants with non-small cell lung cancer (NSCLC). Each treatment cycle lasts 21 days. Participants will swallow SLC-391 pills two times every day. Participants will get pembrolizumab intravenously (IV) from the study site staff on the first day of every cycle. This study has 2 parts. The first part will determine the recommended dose of SLC-391 in combination with pembrolizumab. The second part wants to find out if the combination of SLC-391 and pembrolizumab can help stop NSCLC tumours from growing or spreading.

NCT ID: NCT05725915 Recruiting - Clinical trials for Lung Cancer, Nonsmall Cell

Prediction Model of ICIs Combined With Chemotherapy in Advanced NSCLC

Start date: December 1, 2022
Phase:
Study type: Observational

The reliable predictive markers to identify which patients with advanced non-small cell lung cancer tumors will achieve durable clinical benefit for chemo-immunotherapy are needed. This study is a real world study, aiming to establish a multi-parameter model to predict the efficacy of immune checkpoint inhibitor(ICI) combined with chemotherapy, and to explore the correlation and predictive value of each single biomarker, so as to assist physician to select patients who may benefit for a long time as early as possible and guide clinical accurate treatment.

NCT ID: NCT05537922 Recruiting - Clinical trials for Non Small Cell Lung Cancer

I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy

Start date: October 1, 2022
Phase:
Study type: Observational

I3LUNG is an international project aiming to develop a medical device to predict immunotherapy efficacy for NSCLC patients using the integration of multisource data (real word and multi-omics data). This objective will be reached through a retrospective - setting up a transnational platform of available data from 2000 patients - and a prospective - multi-omics prospective data collection in 200 NSCLS patients - study phase. The retrospective cohort will be used to perform a preliminary knowledge extraction phase and to build a retrospective predictive model for IO (R-Model), that will be used in the prospective study phase to create a first version of the PDSS tool, an AI-based tool to provide an easy and ready-to-use access to predictive models, increasing care appropriateness, reducing the negative impacts of prolonged and toxic treatments on wellbeing and healthcare costs. The prospective part of the project includes the collection and the analysis of multi-OMICs data from a multicentric prospective cohort of about 200 patients. This cohort will be used to validate the results obtained from the retrospective model through the creation of a new model (P-Model), which will be used to create the final PDSS tool.

NCT ID: NCT05415358 Recruiting - Clinical trials for Lung Cancer, Nonsmall Cell

Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients

Start date: January 17, 2023
Phase:
Study type: Observational

The purpose of this study is to examine the association between ctDNA/immune biomarkers and disease progression in patients who, at immunotherapy discontinuation, have completed at least 20 of an anticipated 24 months of pembrolizumab monotherapy or pembrolizumab-combination chemotherapy for mNSCLC.

NCT ID: NCT05384873 Recruiting - Clinical trials for Lung Cancer, Nonsmall Cell

Immunonutrition for Improving the Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer

MURAL
Start date: June 1, 2023
Phase: N/A
Study type: Interventional

The present study was designed to evaluate the efficacy of the early systematic provision of oral nutritional supplements enriched in immunonutrients in non-small lung cancer patients undergoing immunotherapy and receiving nutritional counseling

NCT ID: NCT05085028 Recruiting - Clinical trials for Lung Cancer, Nonsmall Cell

A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

REFINE-Lung
Start date: June 23, 2022
Phase: Phase 3
Study type: Interventional

REFINE-lung will test whether reduced pembrolizumab dose frequency after 6 months of standard treatment is safe and effective. Patients treated with 1st line pembrolizumab who are progression free and otherwise planning to continue therapy at 6 months will be initially randomised to control 6 weekly versus interventional 12 weekly therapy. If an interim analysis shows that the 12 weekly treatment is no less effective, subsequent patients will also be randomised to 9, 15 and 18 weekly treatment frequency arms. Patients who progress on a reduced frequency arm will be offered re-escalation to standard 6 weekly therapy.

NCT ID: NCT04691817 Recruiting - Clinical trials for Lung Cancer, Nonsmall Cell

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Start date: July 25, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.

NCT ID: NCT04638582 Recruiting - Clinical trials for Lung Cancer, Nonsmall Cell

Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)

Start date: August 28, 2022
Phase: Phase 2
Study type: Interventional

This is a prospective, randomized, single-site, open-label Phase II trial of neoadjuvant pembrolizumab (3 cycles) followed by surgery, versus concomitant neoadjuvant pembrolizumab with platinum doublet chemotherapy (3 cycles) followed by surgery for participants with Stage IA3, IB and IIA non-small-cell lung cancer (NSCLC). Participants will be offered pembrolizumab (6 cycles), and standard of care adjuvant chemotherapy (4 cycles) if applicable.